Sector Guides
How to Analyze Pharma Generics Stocks in India: Price Erosion & ANDA
Team QuartrlyPharma generics earnings hinge on how well a company offsets structural US price erosion with specialty products, ANDA approvals, and a clean FDA inspection record. Dr. Reddy's North America revenue fell 13% in Q2 FY25 on price erosion in products including Lenalidomide, while Sun Pharma's US specialty sales exceeded its generics sales for the first time that same quarter and Cipla's India chronic-therapy mix rose to 61.8% — three very different ways of managing the same commodity pricing pressure.
Key Takeaways
- Price Erosion is the defining challenge of US generics — expect 5-10% annual price declines on existing products.
- Specialty Revenue percentage indicates whether a company has escaped the commodity trap and built pricing power.
- Chronic vs. Acute Mix reveals revenue predictability — a higher chronic mix means more stable, recurring revenue.
- FDA compliance (Form 483 observations) can make or break US market access overnight.
Quick Reference
| Metric | Definition | Healthy Range | Warning Sign |
|---|---|---|---|
| Price Erosion | Annual price decline on existing portfolio | 4-6% (mid-single digit) | >10% (double-digit) |
| Specialty Revenue % | Complex/branded products as % of sales | >25-30% of US revenue | 0% (pure commodity) |
| Chronic Mix | Long-term therapy % of India sales | >50% | Heavy acute dependence |
| ANDA Pipeline | Pending US drug applications | 50-100+ with consistent approvals | High pending, low approval rate |
| FDA Status | Facility compliance standing | Zero 483 observations | Data integrity citations |
| R&D % of Revenue | Investment in product development | 5-8% of revenue | <4% (underinvestment) |
Understanding Pharma Generics Metrics
Generic pharmaceutical companies do not develop new molecules. Instead, they manufacture drugs whose patents have expired, competing with other generic manufacturers on price, quality, and speed to market. This creates a business model where manufacturing efficiency and regulatory compliance matter more than R&D breakthroughs.
The US market is particularly important for Indian pharma companies such as Sun Pharma, Dr. Reddy's, Cipla, and Lupin, given its size and higher realizations. However, the US generics market is intensely competitive, with prices declining year-over-year as more manufacturers enter each drug category. Investors tracking this sector must understand metrics that reveal whether a company can maintain margins despite this structural price deflation.
Price Erosion
What it is: Price Erosion measures the percentage decline in average selling prices for a company's existing drug portfolio compared to the prior year. It reflects the competitive pressure on generic drug pricing, particularly in the US market.
Why it matters: Price erosion is the fundamental challenge of the generics business. Even without losing market share, a company's revenue will decline if prices fall faster than volume grows. This metric reveals whether management can offset pricing pressure through new launches and operational efficiency.
What good looks like: Mid-single-digit erosion (4-6% annually) is considered manageable for well-diversified portfolios. Companies with complex generics or limited-competition products may experience lower erosion of 2-4%.
Red flag: Double-digit price erosion (10%+ annually) indicates intense competitive pressure. If revenue growth lags volume growth, the company is effectively running faster to stay in place.
Example from earnings call:
"Revenues in the North America segment declined 13% primarily due to increased price erosion in certain key products, including Lenalidomide." — Dr. Reddy's Q2 FY25 Earnings Call
Specialty Revenue Percentage
What it is: Specialty Revenue refers to sales from complex, differentiated products such as branded drugs, complex injectables, inhalers, biosimilars, or products with proprietary formulations. Specialty Revenue Percentage is calculated as specialty sales divided by total sales.
Why it matters: Specialty products offer pricing power that commodity generics do not. A growing specialty contribution indicates the company is building a portfolio that competitors cannot easily replicate, providing insulation from price erosion.
What good looks like: For large Indian pharma companies, specialty contribution above 25-30% of US revenue signals a differentiated portfolio. Sun Pharma leads with specialty sales exceeding generics for the first time in Q2 FY25.
Red flag: Companies with 100% dependence on simple oral solids (plain tablets and capsules) remain vulnerable to any competitor with manufacturing capability and regulatory approval.
Example from earnings call:
"US specialty sales exceeded generics for the first time. Global specialty sales up 16% YoY." — Sun Pharma Q2 FY25 Earnings Call
Chronic vs. Acute Mix
What it is: Chronic Mix refers to the percentage of sales from therapies for long-term conditions (diabetes, cardiovascular, CNS disorders) versus Acute Mix from short-term treatments (antibiotics, pain management, anti-infectives). This metric is most relevant for the India domestic business.
Why it matters: Chronic therapies generate recurring revenue as patients require continuous medication. Acute therapies depend on disease incidence, making revenue more variable. A higher chronic mix indicates more predictable, stable cash flows.
What good looks like: A chronic mix above 50% is considered favorable for the India domestic business. Cipla reported a chronic mix of 61.8% in Q2 FY25, indicating strong positioning in lifestyle-disease therapies.
Red flag: Heavy dependence on acute therapies (anti-infectives, pain management) exposes revenue to seasonal variations and public health trends. A weak flu season can significantly impact quarterly results.
Example from earnings call:
"Our overall chronic mix further strengthened to 61.8% year-on-year." — Cipla Q2 FY25 Earnings Call
ANDA Filings and Approvals
What it is: An Abbreviated New Drug Application (ANDA) is the regulatory filing required to sell a generic drug in the United States. The FDA reviews ANDAs to confirm the generic is bioequivalent to the reference branded drug. The ANDA pipeline refers to the number of applications pending FDA approval.
Why it matters: Each approved ANDA represents a new revenue opportunity. The pipeline of pending ANDAs indicates future growth potential. The velocity of approvals (approvals received per quarter) reveals whether the company's regulatory and R&D capabilities are producing results.
What good looks like: A robust pipeline of 50-100+ pending ANDAs combined with consistent approval velocity of 8-15 approvals per quarter indicates a healthy product development engine.
Red flag: A high number of pending ANDAs with low approval rates may indicate quality issues with submissions, leading to FDA rejections or requests for additional information.
Example from earnings call:
"As of Sept. 30, 2025, a total of 75 generic filings were pending approval from the FDA, comprising 73 abbreviated new drug applications." — Dr. Reddy's Q2 FY25 Earnings Call
FDA Compliance Status (Form 483)
What it is: A Form 483 is issued by the US FDA following a facility inspection when investigators observe conditions that may violate FDA regulations. The form lists specific observations that require corrective action. Clean inspections result in zero observations.
Why it matters: FDA compliance determines US market access. A Form 483 with serious observations can escalate to a Warning Letter or Import Alert, effectively banning that facility from exporting to the US. For companies deriving 30-40% of revenue from the US, this represents existential risk.
What good looks like: Inspections concluding with zero observations, or minor procedural observations that are easily remediated. A consistent compliance history across multiple facilities.
Red flag: Form 483s citing "data integrity" issues are particularly serious — this indicates potential falsification of records and can result in extended import bans. Multiple facilities under regulatory scrutiny compounds the risk.
R&D Spend as Percentage of Revenue
What it is: R&D Spend Percentage is calculated by dividing research and development expenditure by total revenue. It measures how much the company reinvests in developing new products, formulations, and manufacturing capabilities.
Why it matters: In a business facing structural price erosion, continuous product development is essential to replace declining revenue from older products. R&D spend indicates management's commitment to future growth versus short-term profit extraction.
What good looks like: Indian pharma companies typically spend 5-8% of revenue on R&D. Sun Pharma reported R&D spend of 5.4% (₹7.8 billion) in Q2 FY25, with full-year guidance of 6-8%.
Red flag: R&D spend below 4% may indicate underinvestment in the product pipeline. However, very high R&D spend (above 12%) without corresponding revenue growth raises questions about R&D productivity.
Example from earnings call:
"R&D spend came in at Rs 7.8bn, representing 5.4% of revenues. Full-year guidance expected at lower end of 6%–8%." — Sun Pharma Q2 FY25 Earnings Call
Special Considerations: The First-to-File Exclusivity Trap
Generic pharma investors should understand the 180-day exclusivity provision in US regulations. When a generic company is the first to challenge a patent (Paragraph IV certification), the FDA may grant 180 days of marketing exclusivity — a period where only that company can sell the generic.
During exclusivity, the company enjoys high margins with limited competition. However, when the exclusivity period ends, multiple competitors enter simultaneously, and prices can collapse by 80-90% within months.
Investors should scrutinize whether reported earnings growth stems from sustainable base-business improvement or temporary exclusivity benefits. Dr. Reddy's Lenalidomide (generic Revlimid) is a notable example — exclusivity-driven revenue must be assessed separately from ongoing operations.